Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2271773 | 0.91 | TTR (0.37) | SUCNR1 | |
| SCHEMBL2276039 | 0.91 | BCAT2 (0.38) | SUCNR1 | |
| SCHEMBL2279008 | 0.83 | GRIN2B (0.38) | SUCNR1KMO | |
| SCHEMBL2272544 | 0.78 | PDE4A (0.41) | — | |
| Trifluoroacetic Acid SCHEMBL2277163 | 0.78 | SUCNR1 (0.48) | SUCNR1GRIK1GRIA2 | |
| SCHEMBL2274256 | 0.74 | PDE4D (0.40) | — | |
| SCHEMBL21590503 | 0.74 | GRIN1 (0.43) | — | |
| SCHEMBL21722955 | 0.74 | SCN9A (0.43) | — | |
| SCHEMBL2277088 | 0.72 | PDE4A (0.42) | — | |
| SCHEMBL2285170 | 0.72 | SLC6A4 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575364-B2 | Modulators of serotonin receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-05 | — | — | US | claimed |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | claimed |
| WO-2010059390-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | claimed |
| US-8957059-B2 | Modulators of serotonin receptors | JANSSEN PHARMACEUTICA NV (BG) | 2015-02-17 | — | — | US | disclosed |
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575364-B2 | Modulators of serotonin receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-05 | — | — | US | disclosed |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| WO-2010059390-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR1A, HTR2A, HTR6 | DHODH 2228/4885SUCNR1 110/4885GRIK1 365/4885 |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | HTR1A, HTR6, HTR2A | DHODH 2220/4885SUCNR1 110/4885GRIK1 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.